Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers

Jusoh, A Rashid; Mohan, Sivanesan Vijaya; Lu Ping, Tan; Tengku Din, Tengku Ahmad Damitri Al Astani Bin; Haron, Juhara; Romli, Roslini Che; Jaafar, Hasnan; Nafi, Siti Norasikin; Tuan Salwani, Tuan Ismail; Yahya, Maya Mazuwin

doi:10.31557/APJCP.2021.22.5.1375

Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers

Document Type : Research Articles

Authors

A Rashid Jusoh ¹
Sivanesan Vijaya Mohan ²
Tan Lu Ping ²
Tengku Ahmad Damitri Al Astani Bin Tengku Din ³
Juhara Haron ³^{, 4}
Roslini Che Romli ⁵
Hasnan Jaafar ⁴
Siti Norasikin Nafi ⁵
Tuan Ismail Tuan Salwani ⁶
Maya Mazuwin Yahya ³^{, 6}

¹ Department of Biomedicine, School of Health Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.

² Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, Ministry of Health, Kuala Lumpur, Malaysia.

³ Department of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.

⁴ Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.

⁵ Breast Cancer Awareness and Research Unit, Hospital Universiti Sains Malaysia, Kelantan, Malaysia.

⁶ Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.

10.31557/APJCP.2021.22.5.1375

Abstract

Objective: This study aimed to characterize the miRNA expression profiles from plasma samples of our local breast cancer patients in comparison to healthy control by using miRNA PCR Array. Methods: In this study, plasma miRNA profiles from eight early-stage breast cancer patients and nine age-matched (± 2 years) healthy controls were characterized by miRNA array-based approach, followed by differential gene expression analysis, Independent T-test and construction of Receiver Operating Characteristic (ROC) curve to determine the capability of the assays to discriminate between breast cancer and the healthy control. Results: Based on the 372-miRNAs microarray profiling, a set of 40 differential miRNAs was extracted regarding to the fold change value at 2 and above. We further sub grouped 40 miRNAs of breast cancer patients that were significantly expressed at 2-fold change and higher. In this set, we discovered that 24 miRNAs were significantly upregulated and 16 miRNAs were significantly downregulated in breast cancer patients, as compared to the miRNA expression of healthy subjects. ROC curve analysis revealed that seven miRNAs (miR-125b-5p, miR-142-3p, miR-145-5p, miR-193a-5p, miR-27b-3p, miR-22-5p and miR-423-5p) had area under curve (AUC) value > 0.7 (AUC p-value < 0.05). Overlapping findings from differential gene expression analysis, ROC analysis, and Independent T-Test resulted in three miRNAs (miR-27b-3p, miR-22-5p, miR-145-5p). Cohen’s effect size for these three miRNAs was large with d value are more than 0.95. Conclusion: miR-27b-3p, miR-22-5p, miR-145-5p could be potential biomarkers to distinguish breast cancer patients from healthy controls. A validation study for these three miRNAs in an external set of samples is ongoing.

Keywords